dysregul
ubiquitinproteasom
system
up
implic
wide
rang
patholog
includ
cancer
neurodegener
viral
infect
inhibit
proteasom
shown
effect
therapeut
strategi
human
yet
toxic
target
remain
high
deubiquitin
enzym
dub
repres
altern
target
up
low
predict
toxic
current
dub
inhibitor
enter
clinic
address
situat
progenra
develop
novel
assay
measur
proteolyt
cleavag
ubiquitin
ubl
ubiquitin
like
protein
conjug
sumo
isopeptidas
discuss
current
platform
detect
dub
inhibitor
underlin
advantag
disadvantag
approach
conjug
ubiquitin
ub
ubiquitinlik
ubl
protein
import
regulatori
mechan
widespread
mani
biolog
process
assort
diseas
associ
pathway
make
pathway
enzym
particularli
interest
therapeut
target
up
valid
approv
proteasom
inhibitor
bortezomib
treatment
multipl
myeloma
howev
signific
toxic
seen
clinic
trial
suggest
need
select
target
uband
ublisopeptidas
repres
uniqu
set
drug
target
up
respons
remov
ubiquitin
ubl
sumo
target
protein
thu
affect
target
fate
develop
therapeut
agent
target
isopeptidas
develop
readili
quantifi
novel
isopeptidas
assay
platform
suitabl
highthroughput
screen
ht
assay
platform
consist
ub
ubl
fuse
report
enzym
phospholipas
pla
isopeptidas
activ
releas
pla
cleav
substrat
gener
signal
linear
isopeptidas
concentr
abl
discrimin
dub
desumoylas
deneddylas
deisgylas
activ
assay
success
employ
screen
inhibitor
isopeptidas
approv
proteasom
inhibitor
bortezomib
velcad
treatment
multipl
myeloma
valid
target
ubiquitinproteasom
pathway
up
treatment
cancer
howev
extend
treatment
bortezomib
associ
toxic
drug
resist
limit
efficaci
contrast
therapeut
strategi
target
specif
aspect
ubiquitinproteasom
pathway
upstream
proteasom
would
predict
lower
toxic
activ
enzym
conjug
enzym
upstream
proteasom
one
must
awar
consequ
target
disrupt
lead
cell
cycl
arrest
shown
requir
develop
target
ubiquitin
activ
enzym
may
predict
affect
mani
cellular
function
toler
normal
cell
yet
target
enzym
inhibit
report
success
preclin
studi
mechan
action
like
inactiv
cullinbas
ligas
mani
play
crucial
role
cell
cycl
checkpoint
whose
disrupt
would
immedi
effect
rapidli
divid
cancer
cell
ligas
limit
number
substrat
repres
attract
drug
target
up
one
interest
target
protein
complex
scf
scf
complex
consist
mani
variabl
fbox
adaptor
protein
target
substrat
ubiquitin
two
therapeut
relev
fbox
protein
play
key
role
cell
cycl
progress
howev
inhibit
protein
one
must
disrupt
proteinprotein
interact
consid
difficult
target
enzymat
target
isopeptidas
belong
five
subfamili
identifi
date
four
five
famili
cystein
proteas
shown
good
therapeut
target
ubiquitin
ctermin
hydrolas
uch
ubiquitinspecif
proteas
ubpusp
machadojoseph
domain
mjd
ovarian
tumor
relat
otu
isopeptidas
cystein
proteas
metalloenzym
jamm
motif
dub
zn
metaloproteas
put
dub
identifi
like
function
also
mani
ublisopeptidas
good
therapeut
target
sever
isopeptidas
implic
diseas
particular
cancer
refer
tabl
exampl
ubiquitinspecif
proteas
also
known
herpesvirusassoci
ubiquitinspecif
proteas
regul
ubiquitin
state
ringfing
ligas
human
homolog
target
tumor
suppressor
ubiquitin
facilit
degrad
proteasom
mani
ringfing
ligas
capabl
autoubiquitin
except
autoubiquitin
result
proteolyt
degrad
howev
also
ubiquitin
result
degrad
via
proteasom
initi
believ
primarili
deubiquitin
increas
level
howev
recent
genet
biochem
studi
found
respect
primari
target
data
corrobor
structur
biolog
studi
reveal
recogn
tumor
necrosi
factorreceptor
associ
factor
traf
domain
mutual
exclus
manner
bind
traf
domain
higher
affin
dub
receiv
attent
proteas
deconjug
ubl
target
protein
also
link
variou
pathophysiolog
critic
cellular
local
transcript
regul
signal
transduct
pathway
regul
ubiquitin
ligas
mani
assay
current
use
reli
cleavag
linear
ubfus
produc
ecoli
tetraub
ubdhfr
ubpestc
etc
synthes
chemic
small
scale
analysi
isopeptidas
activ
reaction
product
analyz
gel
electrophoresi
select
precipit
analyz
liquid
scintil
spectrometri
gelbas
procedur
labor
intens
expens
scintil
count
approach
quantit
allow
process
larger
number
sampl
gelbas
assay
requir
centrifug
recoveri
supernat
ht
fluorogen
substrat
ubamc
employ
case
well
similar
substrat
tetrapeptid
zlrggamc
mimic
carboxyl
terminu
ubiquitin
limit
factor
fluoresc
substrat
fact
small
adduct
hydrolyz
effici
largest
class
dub
ubspecif
proteas
ubpusp
class
enzym
moreov
excit
wavelength
ubamc
uv
rang
known
excit
number
screen
compound
give
rise
fals
posit
fluoresc
reson
energi
transfer
fret
also
develop
ht
screen
amc
fret
howev
suffer
need
special
custom
reagent
equip
well
difficulti
adapt
multiwel
plate
format
endpoint
read
directli
mani
approach
expens
doublelabel
tag
substrat
must
gener
specif
assay
refer
tabl
comparison
current
technolog
isopeptidas
interest
time
knowledg
compound
enter
clinic
trial
one
reason
could
assay
employ
drug
discoveri
campaign
previous
describ
platform
base
ub
link
small
chemic
adduct
relat
physiolog
target
isopeptidas
monoor
polyubiquitin
fuse
protein
fulfil
need
conveni
physiolog
relev
assay
suitabl
high
throughput
screen
progenra
develop
isopeptidas
assay
base
observ
usp
hydrolyz
linear
ub
fusion
bond
well
isopeptid
linkag
exploit
requir
certain
protein
free
nterminu
activ
assay
use
either
dub
ulp
ublpla
assay
base
concept
pla
requir
free
amino
terminu
catalyt
activ
pla
cleav
phospholipid
produc
lysophospholipid
free
fatti
acid
requir
free
nterminu
catalyt
activ
pla
fuse
ubl
inact
cleav
substrat
dub
ubl
isopeptidas
present
cleav
ubl
pla
free
pla
act
substrat
number
commerci
substrat
pla
includ
fluoresc
phospholipid
c
hpc
amino
nbd
c
hpc
fluoresc
respons
produc
substrat
occur
wavelength
rang
better
suit
drug
discoveri
employ
ubamc
assay
amplifi
coupl
dub
catalyt
activ
pla
result
enhanc
sensit
importantli
ub
ublpla
fusion
protein
repres
physiolog
substrat
short
carboxi
termin
adduct
exemplifi
commerci
avail
amc
trfret
reagent
knowledg
dub
inhibitor
enter
clinic
trial
howev
modul
dub
cyld
pathway
aspirin
shown
therapeut
viabl
human
progenra
proprietari
assay
technolog
use
multipl
group
screen
compound
date
number
expect
doubl
end
due
increas
screen
perform
isopeptidas
research
anticip
multipl
dub
inhibitor
enter
clinic
near
futur
tabl
isopeptidas
implic
variou
diseas
cancer
hausp
cyld
ubpi
stambp
amsh
neurodegener
ataxin
hematolog
viral
infect
usp
hmwp
bacteri
infect
ssel
elad
